NCT03849651 · OUTCOME

The Number of Patients Experiencing Blinatumomab Permanent Discontinuation Due to Toxicity

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 28 days after receiving first dose of Blinatumomab (up to approximately 7 months post-transplant)

What was measured

If the drug is held for more than 2 weeks due to toxicity, it will be permanently discontinued

Analysis population: Patients who met eligibility criteria, received transplant, and received blinatumomab.

Groups in this outcome

All Transplant Participants

Patients who met eligibility criteria and received transplant during the dose-finding phase.

Dose 1

Patients who met eligibility criteria, received transplant, received 1x10\^5 cells/kg, and received blinatumomab

Dose 2

Patients who met eligibility criteria, received transplant, received 1x10\^6 cells/kg, and received blinatumomab

Dose 3

Patients who met eligibility criteria, received transplant, received 1x10\^7 cells/kg, and received blinatumomab

Phase 2

Patients who met eligibility criteria, received transplant, and were assigned the MED dose of 1x10\^7 cells/kg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Transplant Participants	26
Dose 1	5
Dose 2	3
Dose 3	8
Phase 2	10

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Transplant Participants	3	Not reported	Not reported	Not reported	Not reported
Dose 1	0	Not reported	Not reported	Not reported	Not reported
Dose 2	0	Not reported	Not reported	Not reported	Not reported
Dose 3	1	Not reported	Not reported	Not reported	Not reported
Phase 2	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
3
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
2

denoms

counts
group Id
OG000
value
26
group Id
OG001
value
5
group Id
OG002
value
3
group Id
OG003
value
8
group Id
OG004
value
10
units
Participants

description

If the drug is held for more than 2 weeks due to toxicity, it will be permanently discontinued

groups

description
Patients who met eligibility criteria and received transplant during the dose-finding phase.
id
OG000
title
All Transplant Participants
description
Patients who met eligibility criteria, received transplant, received 1x10\^5 cells/kg, and received blinatumomab
id
OG001
title
Dose 1
description
Patients who met eligibility criteria, received transplant, received 1x10\^6 cells/kg, and received blinatumomab
id
OG002
title
Dose 2
description
Patients who met eligibility criteria, received transplant, received 1x10\^7 cells/kg, and received blinatumomab
id
OG003
title
Dose 3
description
Patients who met eligibility criteria, received transplant, and were assigned the MED dose of 1x10\^7 cells/kg
id
OG004
title
Phase 2

param Type

COUNT_OF_PARTICIPANTS

population Description

Patients who met eligibility criteria, received transplant, and received blinatumomab.

reporting Status

POSTED

time Frame

28 days after receiving first dose of Blinatumomab (up to approximately 7 months post-transplant)

title

The Number of Patients Experiencing Blinatumomab Permanent Discontinuation Due to Toxicity

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice